For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Annexon, Inc. (ANNX - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Annexon, Inc. is a member of the Medical sector. This group includes 1077 individual stocks and currently holds a Zacks Sector Rank of #5. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Annexon, Inc. is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for ANNX's full-year earnings has moved 4.6% higher within the past quarter. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Our latest available data shows that ANNX has returned about 1.3% since the start of the calendar year. At the same time, Medical stocks have lost an average of 1.1%. This shows that Annexon, Inc. is outperforming its peers so far this year.
Another Medical stock, which has outperformed the sector so far this year, is Novartis (NVS - Free Report) . The stock has returned 7.2% year-to-date.
In Novartis' case, the consensus EPS estimate for the current year increased 0.6% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Annexon, Inc. is a member of the Medical - Biomedical and Genetics industry, which includes 523 individual companies and currently sits at #91 in the Zacks Industry Rank. This group has lost an average of 13.3% so far this year, so ANNX is performing better in this area.
On the other hand, Novartis belongs to the Large Cap Pharmaceuticals industry. This 11-stock industry is currently ranked #69. The industry has moved +15.1% year to date.
Investors interested in the Medical sector may want to keep a close eye on Annexon, Inc. and Novartis as they attempt to continue their solid performance.
Zacks Reveals ChatGPT "Sleeper" Stock
One little-known company is at the heart of an especially brilliant Artificial Intelligence sector. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion.
As a service to readers, Zacks is providing a bonus report that names and explains this explosive growth stock and 4 other "must buys." Plus more.
Download Free ChatGPT Stock Report Right Now >>
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Annexon, Inc. (ANNX - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Annexon, Inc. is a member of the Medical sector. This group includes 1077 individual stocks and currently holds a Zacks Sector Rank of #5. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Annexon, Inc. is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for ANNX's full-year earnings has moved 4.6% higher within the past quarter. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Our latest available data shows that ANNX has returned about 1.3% since the start of the calendar year. At the same time, Medical stocks have lost an average of 1.1%. This shows that Annexon, Inc. is outperforming its peers so far this year.
Another Medical stock, which has outperformed the sector so far this year, is Novartis (NVS - Free Report) . The stock has returned 7.2% year-to-date.
In Novartis' case, the consensus EPS estimate for the current year increased 0.6% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Annexon, Inc. is a member of the Medical - Biomedical and Genetics industry, which includes 523 individual companies and currently sits at #91 in the Zacks Industry Rank. This group has lost an average of 13.3% so far this year, so ANNX is performing better in this area.
On the other hand, Novartis belongs to the Large Cap Pharmaceuticals industry. This 11-stock industry is currently ranked #69. The industry has moved +15.1% year to date.
Investors interested in the Medical sector may want to keep a close eye on Annexon, Inc. and Novartis as they attempt to continue their solid performance.
Zacks Reveals ChatGPT "Sleeper" Stock
One little-known company is at the heart of an especially brilliant Artificial Intelligence sector. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion.
As a service to readers, Zacks is providing a bonus report that names and explains this explosive growth stock and 4 other "must buys." Plus more.
Download Free ChatGPT Stock Report Right Now >>
Get the latest research report on NVS - FREE
Get the latest research report on ANNX - FREE